The expressions of MIF and CXCR4 protein in tumor microenvironment are adverse prognostic factors in patients with esophageal squamous cell carcinoma

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Zhang, Lin ^a   Ye, Shu Biao ^a   Ma, Gang ^a   Tang, Xiao Feng ^a   Chen, Shi Ping ^a   He, Jia ^a   Liu, Wan Li ^a   Xie, Dan ^a   Zeng, Yi Xin ^a   Li, Jiang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CXCR4; Esophageal squamous cell carcinoma; MIF; Prognosis; Tumor microenvironment

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL POPULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOCHEMISTRY; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTORS, CXCR4; REGRESSION ANALYSIS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84874745141     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-60     Document Type: Article

References (51)

1. Yan W, Wistuba II, Emmert-Buck MR, Erickson HS. Squamous cell carcinoma - similarities and differences among anatomical sites. American journal of cancer research 2011, 1:275-300. 3175764,3175764, 21938273.
2. Gao Y, Hu N, Han XY, Ding T, Giffen C, Goldstein AM, Taylor PR. Risk factors for esophageal and gastric cancers in Shanxi Province, China: a case-control study. Cancer Epidemiol 2011, 35:e91-e99. 10.1016/j.canep.2011.06.006, 3215853, 21846596.
3. Aghcheli K, Marjani HA, Nasrollahzadeh D, Islami F, Shakeri R, Sotoudeh M, Abedi-Ardekani B, Ghavamnasiri MR, Razaei E, Khalilipour E. Prognostic factors for esophageal squamous cell carcinoma-a population-based study in Golestan Province, Iran, a high incidence area. PLoS One 2011, 6:e22152. 10.1371/journal.pone.0022152, 3141005, 21811567.
4. Wu C, Hu Z, He Z, Jia W, Wang F, Zhou Y, Liu Z, Zhan Q, Liu Y, Yu D. Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet 2011, 43:679-684. 10.1038/ng.849, 21642993.
5. Zhang H, Chen Z, Cheng J, Zhu X, Guo W, Hu A, Du Y, Zhou Y, Wang Y. The high incidence of esophageal cancer in parts of China may result primarily from genetic rather than environmental factors. Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus / ISDE 2010, 23:392-397.
6. Akita H, Doki Y, Miyata H, Hirao T, Yano M, Takachi K, Miyashiro I, Sasaki Y, Ishikawa O, Ohigashi H, Imaoka S. Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. J Surg Oncol 2006, 93:401-409. 10.1002/jso.20501, 16550577.
7. Cao W, Chen X, Dai H, Wang H, Shen B, Chu D, McAfee T, Zhang ZF. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China. Cancer 2004, 101:834-844. 10.1002/cncr.20437, 15305417.
8. Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, Chen JG, Chen YB, Yun JP, Xia JC. The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One 2011, 6:e18219. 10.1371/journal.pone.0018219, 3069054, 21483813.
9. Huang C, Fu ZX. Localization of IL-17+Foxp3+ T cells in esophageal cancer. Immunol Investig 2011, 40:400-412.
10. Liang Y, Hou X, Cui Q, Kang TB, Fu JH, Zhang LJ, Luo RZ, He JH, Zeng YX, Yang HX. Skp2 expression unfavorably impacts survival in resectable esophageal squamous cell carcinoma. J Transl Med 2012, 10:73. 10.1186/1479-5876-10-73, 3356230, 22533738.
11. Wang XC, Tian LL, Tian J, Jiang XY. Overexpression of SKP2 promotes the radiation resistance of esophageal squamous cell carcinoma. Radiat Res 2012, 177:52-58. 10.1667/RR2679.1, 22077337.
12. Fukuchi M, Masuda N, Nakajima M, Fukai Y, Miyazaki T, Kato H, Kuwano H. Inverse correlation between expression levels of p27 and the ubiquitin ligase subunit Skp2 in early esophageal squamous cell carcinoma. Anticancer Res 2004, 24:777-783.
13. Kondo K, Yamasaki S, Inoue N, Sugie T, Teratani N, Kan T, Shimada Y. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma. Surg Today 2006, 36:966-974. 10.1007/s00595-006-3295-5, 17072716.
14. Morand EF. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J 2005, 35:419-426. 10.1111/j.1445-5994.2005.00853.x, 15958113.
15. Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, Bucala R, Shachar I. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008, 283:2784-2792.
16. Schwartz V, Lue H, Kraemer S, Korbiel J, Krohn R, Ohl K, Bucala R, Weber C, Bernhagen J. A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett 2009, 583:2749-2757. 10.1016/j.febslet.2009.07.058, 2911026, 19665027.
17. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007, 13:587-596. 10.1038/nm1567, 17435771.
18. Dumitru CA, Gholaman H, Trellakis S, Bruderek K, Dominas N, Gu X, Bankfalvi A, Whiteside TL, Lang S, Brandau S. Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. Int J Cancer 2011, 129:859-869. 10.1002/ijc.25991, 21328346.
19. Larsen M, Tazzyman S, Lund EL, Junker N, Lewis CE, Kristjansen PE, Murdoch C. Hypoxia-induced secretion of macrophage migration-inhibitory factor from MCF-7 breast cancer cells is regulated in a hypoxia-inducible factor-independent manner. Cancer Lett 2008, 265:239-249. 10.1016/j.canlet.2008.02.012, 18353538.
20. Rendon BE, Roger T, Teneng I, Zhao M, Al-Abed Y, Calandra T, Mitchell RA. Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem 2007, 282:29910-29918. 10.1074/jbc.M704898200, 17709373.
21. Wilson JM, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G, Leng L, Lubetsky JB, Jin KK, Lolis E. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 2005, 129:1485-1503. 10.1053/j.gastro.2005.07.061, 16285950.
22. Chen G, Chen SM, Wang X, Ding XF, Ding J, Meng LH. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J Biol Chem 2012, 287:12132-12141. 10.1074/jbc.M111.302299, 3320958, 22337890.
23. Rigo A, Gottardi M, Zamo A, Mauri P, Bonifacio M, Krampera M, Damiani E, Pizzolo G, Vinante F. Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer 2010, 9:273. 10.1186/1476-4598-9-273, 2964621, 20946648.
24. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004, 64:8604-8612. 10.1158/0008-5472.CAN-04-1844, 15574767.
25. Li J, Mo HY, Xiong G, Zhang L, He J, Huang ZF, Liu ZW, Chen QY, Du ZM, Zheng LM. Tumor microenvironment MIF directs the accumulation of IL-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. J Biol Chem 2012, 28:35484-35495.
26. Liao B, Zhong BL, Li Z, Tian XY, Li Y, Li B. Macrophage migration inhibitory factor contributes angiogenesis by up-regulating IL-8 and correlates with poor prognosis of patients with primary nasopharyngeal carcinoma. J Surg Oncol 2010, 102:844-851. 10.1002/jso.21728, 20872800.
27. O'Sullivan B, Shah J. New TNM staging criteria for head and neck tumors. Semin Surg Oncol 2003, 21:30-42. 10.1002/ssu.10019, 12923914.
28. Domschke C, Schuetz F, Ge Y, Seibel T, Falk C, Brors B, Vlodavsky I, Sommerfeldt N, Sinn HP, Kuhnle MC. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 2009, 69:8420-8428. 10.1158/0008-5472.CAN-09-1627, 19843863.
29. Liu A, Fang H, Dirsch O, Jin H, Dahmen U. Early release of macrophage migration inhibitory factor after liver ischemia and reperfusion injury in rats. Cytokine 2012, 57:150-157. 10.1016/j.cyto.2011.11.009, 22136975.
30. Seike T, Fujita K, Yamakawa Y, Kido MA, Takiguchi S, Teramoto N, Iguchi H, Noda M. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin Exp Metastasis 2011, 28:13-25. 10.1007/s10585-010-9354-8, 2998640, 20953899.
31. Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 2009, 115:2031-2040. 10.1002/cncr.24245, 19326434.
32. Bach JP, Rinn B, Meyer B, Dodel R, Bacher M. Role of MIF in inflammation and tumorigenesis. Oncology 2008, 75:127-133. 10.1159/000155223, 18791328.
33. Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, Gaedcke J, Ghadimi BM, Ried T, Yffantis HG. Macrophage Migration Inhibitory Factor (MIF) induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int J Cancer 2012, 132:785-794.
34. Kant P, Sainsbury A, Reed KR, Pollard SG, Scott N, Clarke AR, Coletta PL, Hull MA. Rectal epithelial cell mitosis and expression of macrophage migration inhibitory factor are increased 3 years after Roux-en-Y gastric bypass (RYGB) for morbid obesity: implications for long-term neoplastic risk following RYGB. Gut 2011, 60:893-901. 10.1136/gut.2010.230755, 21303912.
35. Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, Zarate R, Diaz-Gonzalez JA, Ramirez N, Sola JJ. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 2009, 15:2281-2290. 10.1158/1078-0432.CCR-08-1818, 19318487.
36. Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE, Fitzgerald MC, Bepler G, Patz EF. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 2004, 46:313-323. 10.1016/j.lungcan.2004.05.013, 15541816.
37. Mittelbronn M, Platten M, Zeiner P, Dombrowski Y, Frank B, Zachskorn C, Harter PN, Weller M, Wischhusen J. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathol 2011, 122:353-365. 10.1007/s00401-011-0858-3, 21773885.
38. Yao K, Shida S, Selvakumaran M, Zimmerman R, Simon E, Schick J, Haas NB, Balke M, Ross H, Johnson SW, O'Dwyer PJ. Macrophage migration inhibitory factor is a determinant of hypoxia-induced apoptosis in colon cancer cell lines. Clin Cancer Res 2005, 11:7264-7272. 10.1158/1078-0432.CCR-05-0135, 16243796.
39. Legendre H, Decaestecker C, Nagy N, Hendlisz A, Schuring MP, Salmon I, Gabius HJ, Pector JC, Kiss R. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2003, 16:491-504.
40. Tomiyasu M, Yoshino I, Suemitsu R, Okamoto T, Sugimachi K. Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. Clin Cancer Res 2002, 8:3755-3760.
41. Shkolnik T, Livni E, Reshef R, Lachter J, Eidelman S. The macrophage migration inhibition (MIF) assay as a marker of colorectal cancer. Studies in patients with colorectal cancer, noncolonic neoplasms, and conditions predisposing to colorectal cancer. Dis Colon Rectum 1987, 30:101-105. 10.1007/BF02554942, 3803112.
42. Stojanovic I, Cvjeticanin T, Lazaroski S, Stosic-Grujicic S, Miljkovic D. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology 2009, 126:74-83. 10.1111/j.1365-2567.2008.02879.x, 2632697, 18624729.
43. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149. 10.1182/blood-2009-03-208249, 2723011, 19470694.
44. Erreni M, Mantovani A, Allavena P. Tumor-associated Macrophages (TAM) and inflammation in colorectal cancer. Cancer microenvironment: official journal of the International Cancer Microenvironment Society 2011, 4:141-154.
45. Baron N, Deuster O, Noelker C, Stuer C, Strik H, Schaller C, Dodel R, Meyer B, Bacher M. Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells. J Neurosci Res 2011, 89:711-717. 10.1002/jnr.22595, 21360573.
46. Tarnowski M, Grymula K, Liu R, Tarnowska J, Drukala J, Ratajczak J, Mitchell RA, Ratajczak MZ, Kucia M. Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts. Mol Cancer Res 2010, 8:1328-1343. 10.1158/1541-7786.MCR-10-0288, 2974061, 20861157.
47. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007, 67:585-592. 10.1158/0008-5472.CAN-06-2941, 2679985, 17234767.
48. Spoo AC, Lubbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007, 109:786-791. 10.1182/blood-2006-05-024844, 16888090.
49. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761-1767. 10.1182/blood-2005-08-3182, 16269611.
50. Gockel I, Schimanski CC, Heinrich C, Wehler T, Frerichs K, Drescher D, von Langsdorff C, Domeyer M, Biesterfeld S, Galle PR. Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma. BMC Cancer 2006, 6:290. 10.1186/1471-2407-6-290, 1766934, 17176471.
51. Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005, 97:1840-1847. 10.1093/jnci/dji431, 16368946.